Long Focus Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Long Focus Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-215,000	Closed	-$195K	–	111
2024 Q3	$195K	Hold	215,000	–	–	0.01%	96
2024 Q2	$214K	Hold	215,000	–	–	0.01%	97
2024 Q1	$318K	Hold	215,000	–	–	0.02%	92
2023 Q4	$234K	Hold	215,000	–	–	0.01%	105
2023 Q3	$254K	Hold	215,000	–	–	0.01%	105
2023 Q2	$303K	Hold	215,000	–	–	0.01%	99
2023 Q1	$323K	Hold	215,000	–	–	0.02%	99
2022 Q4	$252K	Hold	215,000	–	–	0.02%	98
2022 Q3	$243K	Hold	215,000	–	–	0.02%	95
2022 Q2	$340K	Hold	215,000	–	–	0.04%	94
2022 Q1	$331K	Hold	215,000	–	–	0.04%	93
2021 Q4	$527K	Buy	+215,000	New	+$503K	0.07%	84

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Long Focus Capital Management's LCTX Position: Q4 2024 in Review

Long Focus Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2024, closing a stake of 215,000 shares — an estimated $195K sold.

Long Focus Capital Management first reported a position in LCTX in Q4 2021 and held it in 12 quarters. The position peaked at $527K in Q4 2021. 126 funds tracked by Wall St. Rank hold LCTX as of Q4 2024.

Long Focus Capital Management reported no remaining Lineage Cell Therapeutics position as of Q4 2024 after selling out during the quarter.
Long Focus Capital Management sold 215,000 Lineage Cell Therapeutics shares in Q4 2024, an estimated $195K.
Long Focus Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2021 and held it in 12 quarters.
Long Focus Capital Management's Lineage Cell Therapeutics position peaked at $527K in Q4 2021.
126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2024.

Based on Long Focus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.